TobaccoReporter logo

Tag: on!

  • Altria Reports Q1 2026 Results; Reaffirms Full-Year Guidance

    Altria Reports Q1 2026 Results; Reaffirms Full-Year Guidance

    Altria Group reported a strong start to 2026, delivering solid financial growth and reaffirming full-year earnings guidance. First-quarter net revenues rose 3.2% to $5.4 billion, while adjusted diluted earnings per share (EPS) increased 7.3% to $1.32, driven by higher operating income and reduced share count. The company continues to generate significant cash flow, enabling shareholder returns through $1.8 billion in dividends and $280 million in share repurchases during the quarter. Management maintained its full-year adjusted EPS outlook of $5.56 to $5.72, reflecting confidence in continued performance despite macroeconomic uncertainty.

    Operationally, Altria’s smokeable products segment remained the primary earnings driver, supported by pricing strength and Marlboro’s continued leadership in the premium category. While overall cigarette shipment volumes declined due to industry contraction, income growth and margin expansion offset these pressures. In the oral tobacco segment, the on! nicotine pouch brand showed volume growth and ongoing national expansion, though competitive dynamics and shifting product mix weighed on margins. The company continues to balance investment in emerging smoke-free products with maintaining profitability in its core combustible business.

    Strategically, Altria said it is advancing its “Moving Beyond Smoking” vision by investing in smoke-free alternatives and long-term growth initiatives. The company is navigating moderated e-vapor category growth, regulatory constraints, and evolving consumer preferences, while also investing in manufacturing capabilities and cost-efficiency programs. Although near-term challenges include declining cigarette volumes and competitive pressure in oral products, Altria said its strong cash generation, disciplined capital allocation, and diversified nicotine portfolio position it to sustain earnings growth and shareholder value over the long term.

  • FDA’s Pouch Fast-Track Scheme Stalling Over Youth Worries

    FDA’s Pouch Fast-Track Scheme Stalling Over Youth Worries

    A fast-track review program at the U.S. Food and Drug Administration aimed at accelerating authorizations for nicotine pouch products has stalled, as agency scientists weigh concerns about youth uptake and risks to non-users against potential harm-reduction benefits for smokers, according to sources cited by Reuters. Reuters said applications tied to pouch brands from Philip Morris International (Zyn) and British American Tobacco (Velo) remain under review despite expectations that decisions would be made by the end of 2025 under the pilot scheme. The FDA has already authorized six products under Altria Group’s on! brand, but reviewers are said to be taking a more cautious stance on other applications where evidence of net public-health benefit is viewed as less clear-cut.

    While FDA data shows pouch use among middle- and high-school students remains relatively low, it has been rising, prompting heightened scrutiny. Tobacco companies argue the pilot program is critical for restoring legal market competition amid a surge of unregulated products, while public-health advocates warn that rapid authorizations could fuel new addiction trends. The FDA said decisions continue to be guided by science and statutory standards rather than external pressure.

  • Altria Moving Forward with Smoke-Free Products

    Altria Moving Forward with Smoke-Free Products

    Altria Group, Inc. reaffirmed its 2026 full-year guidance at the Consumer Analyst Group of New York Conference on February 18, projecting adjusted diluted EPS of $5.56 to $5.72, representing growth of 2.5% to 5.5% from a 2025 base of $5.42. CEO Billy Gifford and CFO Sal Mancuso told investors earnings growth is expected to be weighted toward the second half of the year, driven by a progressive increase in cigarette import and export activity, continued pricing power in the combustibles segment, and capital allocation including share repurchases. The company also emphasized its strategic pivot toward smoke-free products, including its on! nicotine pouch portfolio, positioning reduced-risk categories as a key long-term growth driver as cigarette volumes continue to decline.

    “Long term, it’s important to compete in e-vapor with flavored products that meet evolving consumer preferences,” Gifford said. “We are working on a pipeline of products to drive to that future. The proliferation of illicit disposable products, slow pace of FDA authorizations, and the intellectual property landscape remain significant headwinds. We intend to maintain a measured approach to our investments in e-vapor, until the regulatory framework is functioning as intended and enforcement actions meaningfully address the illicit market.”

  • Altria Reports Q3 Results, Narrows 2025 Guidance

    Altria Reports Q3 Results, Narrows 2025 Guidance

    Altria Group, Inc. reported third-quarter 2025 net revenues of $6.1 billion, down 3% year-on-year, while adjusted diluted EPS rose 3.6% to $1.45. The company reaffirmed its resilience in core tobacco and smoke-free products and announced an expansion of its share repurchase program from $1 billion to $2 billion, set to run through 2026.

    CEO Billy Gifford highlighted “exciting progress” across Altria’s portfolio, including the U.S. launch of on! PLUS nicotine pouches, regulatory submissions for Ploom heated tobacco, and a strategic collaboration with KT&G to pursue international and non-nicotine growth opportunities. The company also marked its 60th dividend increase in 56 years, underscoring its continued focus on shareholder returns.

    Altria narrowed its full-year 2025 adjusted EPS guidance to a range of $5.37–$5.45, representing 3.5%–5.0% growth from 2024. Management said it expects performance to moderate in Q4 as it laps prior share reductions and continues to invest in its smoke-free strategy amid a dynamic regulatory environment.

  • FDA Launches Pilot to Fast-Track Nicotine Pouch Reviews

    FDA Launches Pilot to Fast-Track Nicotine Pouch Reviews

    The U.S. Food and Drug Administration is set to fast-track reviews of nicotine pouches from Philip Morris International, Altria, Reynolds American, and Turning Point Brands in a pilot program launching Monday, according to Reuters. According to transcripts of an agency meeting last Friday, the agency aims to complete assessments by December, providing a quicker path to market for products like Zyn, on!, Velo, Fre, and Alp. The initiative comes amid pressure from the Trump administration to accelerate approvals and streamline the review process for the fastest-growing category of U.S. tobacco alternatives.

    The pilot program will reportedly feature reduced and expedited reviews, more frequent communication between FDA staff and companies, and a focus on essential scientific and safety data, including product characterization, manufacturing consistency, and abuse-liability information. For products already on the market without full authorization, the process could remove uncertainty over legality and potential enforcement actions. Tobacco firms have long lobbied for a faster FDA authorization route, noting that lengthy reviews have allowed competitors to capture market share in the meantime.

    “Adult nicotine and tobacco consumers are increasingly seeking nicotine pouches as a smoke-free alternative, and the industry is rapidly growing in response,” said Laura Leigh Oyler, vice president of U.S. Regulatory Affairs at Haypp Group, who will be speaking at GTNF 2025 in Brussels on the U.S. regulatory landscape. “These consumers deserve a marketplace of FDA-reviewed product choices to support their journey away from more harmful products. 

    “It makes sense that our government should also work to meet the demands of citizens, supporting a regulatory regime that quickly reviews well-designed and well-tested products from responsible and compliant manufacturers. This is a positive step not just for the regulator and the regulated industry, but for the millions of American adults looking for products they can trust.”